NCT05339295View on ClinicalTrials.gov

Bioequivalence Study of Levomerc 500 mg Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 11, 2012

Primary Completion Date

July 20, 2012

Study Completion Date

September 20, 2012

Conditions
HealthyPharmacokintetics
Interventions
DRUG

Levofloxacin 500mg

A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS, Karachi

All Listed Sponsors
collaborator

Merck Pvt. Ltd, Pakistan

UNKNOWN

collaborator

Center for bioequivalence studies and clinical reseach (CBSCR), ICCBS, University of Karachi

UNKNOWN

lead

University of Karachi

OTHER

NCT05339295 - Bioequivalence Study of Levomerc 500 mg Tablets | Biotech Hunter | Biotech Hunter